Latest Articles

Publication Date
All News Scientific
Doctors call for enhanced awareness campaigns on endometriosis - The Star Kenya

Doctors call for enhanced awareness campaigns on endometriosis The Star Kenya

Published: Dec. 9, 2024, 4 p.m.
Read Full Article
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - BioSpace

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer BioSpace

Published: Dec. 6, 2024, 8:22 a.m.
Read Full Article
Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer - OncLive

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer OncLive

Published: Dec. 5, 2024, 7:04 p.m.
Read Full Article
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - The Malaysian Reserve

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer The Malaysian Reserve

Published: Dec. 5, 2024, 3:36 p.m.
Read Full Article
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - Canada NewsWire

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer Canada NewsWire

Published: Dec. 5, 2024, 2:43 p.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire

Published: Dec. 3, 2024, 10:01 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance UK

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance UK

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
Woman forced into life-changing surgery after 10 years of botched medical diagnosis - The Mirror

Woman forced into life-changing surgery after 10 years of botched medical diagnosis The Mirror

Published: Dec. 1, 2024, 4:17 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!